Effect of supplementation in treatment of women with polycystic ovary syndrome

Clinical trial of the effect of combined omega-3 fatty acid and vitamin E supplementation compared with the placebo on hormonal profiles in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201511015623N57

Enrollment

Registered

2015-11-03

Start date

2015-11-01

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Control group: Placebo capsule, daily for 12 weeks orally. Intervention 2: Intervention group: Omega-3 fatty acid and vitamin E capsule, 1000 mg omega-3 fatty acid and 400 mg vitamin E

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Pregnant women Diabetes Uncontrolled hypertension Hypo or hyperthyroidism Liver disease Androgen-secreting tumor Hyperprolactinemia

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Testosterone. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;SHBG. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;DHEAS. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;FPG. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hirsutism. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical observation.	—

Measure

Time frame

Testosterone. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;SHBG. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;DHEAS. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;FPG. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hirsutism. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 913 361 5447

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026